Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084   2/06/2023
6,060 USD (+2,71%)
(+2,71%)   2/06/2023

2 juni 2023 · Vanda Pharmaceuticals Announces Presentations at SLEEP 2023 · Persbericht

2 juni 2023 · Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S · Persbericht

25 mei 2023 · Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness · Persbericht

10 mei 2023 · Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal · Persbericht

5 mei 2023 · Vanda Pharmaceuticals Announces Presentations at DDW 2023 · Persbericht

3 mei 2023 · Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results · Persbericht

2 mei 2023 · Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information · Persbericht

28 april 2023 · Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023 · Persbericht

28 maart 2023 · Vanda Prevails in Jet Lag Litigation Against the FDA · Persbericht

17 maart 2023 · Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors · Persbericht

8 februari 2023 · Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results · Persbericht

2 februari 2023 · Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023 · Persbericht

6 januari 2023 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

19 december 2022 · Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study · Persbericht

16 december 2022 · Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch · Persbericht

13 december 2022 · Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation · Persbericht

2 december 2022 · Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety · Persbericht

9 november 2022 · Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences · Persbericht

2 november 2022 · Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results · Persbericht

27 oktober 2022 · Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022 · Persbericht

Mijn selecties